Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COEP NASDAQ:GLYC NASDAQ:PLUR NASDAQ:STTK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOEPCoeptis Therapeutics$10.72+1.1%$9.22$2.31▼$13.70$37.25M-0.6358,386 shs23,114 shsGLYCGlycoMimetics$0.16-6.6%$13.48$14.06▼$63.00$10.00M1.6267,672 shs1.05 million shsPLURPluri$5.16-2.5%$4.90$3.33▼$7.13$41.64M0.7612,420 shs1,712 shsSTTKShattuck Labs$0.73-3.9%$0.92$0.69▼$3.95$36.48M1.63208,395 shs79,399 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOEPCoeptis Therapeutics+1.13%-7.82%+43.32%+31.53%+122.13%GLYCGlycoMimetics0.00%0.00%0.00%-99.41%-99.29%PLURPluri-2.46%0.00%-4.27%+5.52%-12.69%STTKShattuck Labs-3.89%-13.50%-13.58%-26.48%-81.61%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOEPCoeptis TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AGLYCGlycoMimeticsN/AN/AN/AN/AN/AN/AN/AN/APLURPluri2.0788 of 5 stars3.54.00.00.00.61.70.0STTKShattuck Labs2.9993 of 5 stars3.45.00.00.00.61.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOEPCoeptis Therapeutics 0.00N/AN/AN/AGLYCGlycoMimetics 3.00BuyN/AN/APLURPluri 3.00Buy$12.00132.56% UpsideSTTKShattuck Labs 2.83Moderate Buy$7.50924.59% UpsideCurrent Analyst Ratings BreakdownLatest GLYC, PLUR, STTK, and COEP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025PLURPluriIndustrial Alliance SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$12.006/2/2025PLURPluriAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOEPCoeptis Therapeutics$62.87K599.14N/AN/A$1.61 per share6.66GLYCGlycoMimetics$10K1,000.25N/AN/A$0.08 per share1.94PLURPluri$330K123.06N/AN/A$1.00 per share5.16STTKShattuck Labs$5.72M6.13N/AN/A$1.67 per share0.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOEPCoeptis Therapeutics-$10.88M-$5.80N/A∞N/AN/A-282.39%-127.23%N/AGLYCGlycoMimetics-$37.88M-$0.46N/AN/AN/AN/A-230.74%-177.39%8/6/2025 (Estimated)PLURPluri-$20.89M-$5.53N/A∞N/A-2,563.29%-4,191.91%-85.40%9/16/2025 (Estimated)STTKShattuck Labs-$75.41M-$1.39N/AN/AN/AN/A-79.69%-69.13%8/7/2025 (Estimated)Latest GLYC, PLUR, STTK, and COEP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025STTKShattuck Labs-$0.25N/AN/AN/AN/AN/A5/14/2025Q1 2025COEPCoeptis TherapeuticsN/A-$1.11N/A-$1.11N/AN/A5/14/2025Q1 2025GLYCGlycoMimetics-$5.00-$4.00+$1.00-$0.04N/AN/A5/13/2025Q3 2025PLURPluriN/A-$0.94N/A-$0.94N/A$0.43 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOEPCoeptis TherapeuticsN/AN/AN/AN/AN/AGLYCGlycoMimeticsN/AN/AN/AN/AN/APLURPluriN/AN/AN/AN/AN/ASTTKShattuck LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOEPCoeptis Therapeutics0.020.820.82GLYCGlycoMimeticsN/A1.921.92PLURPluri51.654.814.81STTKShattuck LabsN/A9.089.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOEPCoeptis Therapeutics13.88%GLYCGlycoMimetics75.19%PLURPluri16.59%STTKShattuck Labs58.74%Insider OwnershipCompanyInsider OwnershipCOEPCoeptis Therapeutics24.25%GLYCGlycoMimetics8.70%PLURPluri25.93%STTKShattuck Labs12.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOEPCoeptis Therapeutics23.51 million2.66 millionNot OptionableGLYCGlycoMimetics5064.53 million58.90 millionOptionablePLURPluri1507.87 million5.83 millionOptionableSTTKShattuck Labs10047.90 million42.16 millionOptionableGLYC, PLUR, STTK, and COEP HeadlinesRecent News About These CompaniesHead to Head Contrast: Nexien Biopharma (OTCMKTS:NXEN) and Shattuck Labs (NASDAQ:STTK)August 2 at 2:09 AM | americanbankingnews.comShattuck Labs Elects Directors, Approves Auditor at MeetingJuly 15, 2025 | tipranks.comShattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and MetabolismJuly 2, 2025 | globenewswire.comShattuck Labs, Inc. (STTK) - Yahoo FinanceJune 28, 2025 | finance.yahoo.comHere's Why We're Watching Shattuck Labs' (NASDAQ:STTK) Cash Burn SituationJune 13, 2025 | finance.yahoo.comShattuck Labs Advances SL-325 Program Amid Financial ProgressMay 5, 2025 | tipranks.comShattuck Labs Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 1, 2025 | globenewswire.comShattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | globenewswire.comShattuck Labs Full Year 2024 Earnings: Misses ExpectationsMarch 29, 2025 | uk.finance.yahoo.comShattuck Labs reports Q4 EPS (37c), consensus (32c)March 28, 2025 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Hold Rating on Shattuck Labs (STTK)March 28, 2025 | markets.businessinsider.comShattuck Labs, Inc.: Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business HighlightsMarch 27, 2025 | finanznachrichten.deShattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business HighlightsMarch 27, 2025 | globenewswire.comLeerink Partners Initiates Coverage of Shattuck Labs (STTK) with Outperform RecommendationMarch 18, 2025 | msn.comShattuck Labs initiated with an Outperform at LeerinkMarch 17, 2025 | markets.businessinsider.comFavourable Signals For Shattuck Labs: Numerous Insiders Acquired StockMarch 11, 2025 | finance.yahoo.comH.C. Wainwright Keeps Their Hold Rating on Shattuck Labs (STTK)February 21, 2025 | markets.businessinsider.comShattuck Labs’ SL-325 shows positive results in inflammatory bowel diseaseFebruary 20, 2025 | markets.businessinsider.comShattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025February 20, 2025 | globenewswire.comShattuck Labs to Present Pre-Clinical Data on SL-325 at ECCO 2025 Conference in BerlinFebruary 13, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGLYC, PLUR, STTK, and COEP Company DescriptionsCoeptis Therapeutics NASDAQ:COEP$10.72 +0.12 (+1.13%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$10.42 -0.30 (-2.80%) As of 08/1/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.GlycoMimetics NASDAQ:GLYCGlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.Pluri NASDAQ:PLUR$5.16 -0.13 (-2.46%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$5.40 +0.25 (+4.75%) As of 08/1/2025 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.Shattuck Labs NASDAQ:STTK$0.75 -0.01 (-1.52%) As of 08/1/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
